Ann: Trading Halt, page-90

As previously pointed out the "result" of our present activity is FDA approval granted or denied. The announcement to come here may be that further time is required but a trading halt is not required to announce a delay.

I therefore have every expectation that it will be top-line results from the clinical study, which will be used to support the FDA submission.

The "update" will be one of:
1) the results are disappointing and Resapp have decided to pursue a different level of approval (or none at all).
2) the results are as expected and Resapp are confident that FDA approval will be granted.
3) the results are very good and Resapp are highly confident that FDA approval will be granted.

My money is 60% on 2) and 35% on 3).